Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · second_quarter · 2A
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Source: Senate LDA
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for puposes of negotiating with payers (HR 1409, HR 1946, HR 1839)
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
HR 1409, Legislation to exempt health care providers (including pharmacies) from the antitrust laws for purposes of negotiating with payers.
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Postal Reform proposals and their impact on 6 day mail delivery
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Postal Reform proposals and their impact on 6 day mail delivery
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · first_quarter · Q1
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · fourth_quarter · Q4
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · third_quarter · Q3
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory implementation of various tax provisions in the health reform legislation
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · second_quarter · Q2
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · first_quarter · Q1
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · fourth_quarter · Q4
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · third_quarter · Q3
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · first_quarter · Q1
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · 4A
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · Q4
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · third_quarter · Q3
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
Legislation to exempt certain pharmacies from the antitrust laws for puposes of negotiating with payers (HR 1409, HR 1946, HR 1839)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · first_quarter · Q1
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 1409, Legislation to exempt health care providers (including pharmacies) from the antitrust laws for purposes of negotiating with payers.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as EGWP waivers and MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of Average Manufacture Price in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · fourth_quarter · Q4
Exclusion of specialty distributors' prompt pay discounts from the definition of averages sales price Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap, drug copay waivers. Reform proposals that impact Medicaid such as statutory changes to average manufacture price. General regulatory changes to the Medicare Part D program.
HR. 1204--Pharmacies Antitrust Carve-out Legislation
Regulatory policies related to health reform, structure, PBM and drug benefits--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH (ARRA, HR 1)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · third_quarter · Q3
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · second_quarter · Q2
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
H.R. 1204--Pharmacies Antitrust carve out legislation
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · first_quarter · Q1
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199
H.R. 1204--Pharmacies Antitrust carve out legislation
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3950 and HR 4872 (PPRACA)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · fourth_quarter · Q4
Establishment of a regulatory pathway for biogenerics/biosimilars--S. 1679, HR 1427, HR 1548, S. 726, HR 3962, HR 3950 Items related to the regulatory implementation of HITECH, HR 1 Items relating to health care reform bills, structure, pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act
Items related to reverse settlement payments between manufacturers--HR 1706, S. 369, HR 3590; HR 3962 Items related to oversight of the federal employees health benefits program and its pharmacy benefit Design and coverage of pharmacy benefits in new Health Exchanges/Gateways as well as pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act HR 4199, PHARMACY bill, items related to restricting PBMs ability to manage prescription drug benefits.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Regulatory implementation of various tax provisions in the health reform legislation
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform legislation
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduc.
Trans Pacific Partnership trade agreements impact on biosimilar drugs market exclusivity length.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Implementation of Zadroga Health Care Act; Legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs; regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Zadroga implement.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Items related to reverse settlement payments between manufacturers--HR 1706, S 369; Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489; Regulatory design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements; Policies related to restricting PBMS' ability to manage prescription drug benefits-- HR 4199; PBM Audit Reform & Transparency Act--HR 5234.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
H.R. 1204--Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392, HR 3200 Various regulatory items related to Medicare Part B, Part D and workers' compensation Health reform proposals that would impact Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing Medicare Part D's coverage gap-- HR 3962, Affordable Health Care for America Act HR 3950, Patient Protection and Affordable Care Act
H.R. 1204 -- Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, White House Office